MAP2K7 and melanoma: In melanoma, longitudinal ctDNA assessment predicts overall survival of stage IV melanoma patients treated with either BRAF and MEK inhibitors or immunotherapy [7,8,9,10,11] and the survival of patients with high-risk stage III resected melanoma [12,13,14,15].